ALGS vs. LENZ, CDTX, ENTX, GNTA, AVRO, IKNA, ASMB, TSBX, ELUT, and ATRA
Should you be buying Aligos Therapeutics stock or one of its competitors? The main competitors of Aligos Therapeutics include LENZ Therapeutics (LENZ), Cidara Therapeutics (CDTX), Entera Bio (ENTX), Genenta Science (GNTA), AVROBIO (AVRO), Ikena Oncology (IKNA), Assembly Biosciences (ASMB), Turnstone Biologics (TSBX), Elutia (ELUT), and Atara Biotherapeutics (ATRA). These companies are all part of the "medical" sector.
Aligos Therapeutics (NASDAQ:ALGS) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, valuation, profitability, risk, dividends, earnings and analyst recommendations.
LENZ Therapeutics has a consensus price target of $31.33, suggesting a potential upside of 87.74%. Given LENZ Therapeutics' higher possible upside, analysts plainly believe LENZ Therapeutics is more favorable than Aligos Therapeutics.
Aligos Therapeutics received 18 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 62.16% of users gave Aligos Therapeutics an outperform vote.
60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 16.5% of Aligos Therapeutics shares are owned by insiders. Comparatively, 38.4% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Aligos Therapeutics has a beta of 2.37, meaning that its stock price is 137% more volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500.
In the previous week, LENZ Therapeutics had 15 more articles in the media than Aligos Therapeutics. MarketBeat recorded 20 mentions for LENZ Therapeutics and 5 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.69 beat LENZ Therapeutics' score of 0.52 indicating that Aligos Therapeutics is being referred to more favorably in the media.
LENZ Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -783.72%. LENZ Therapeutics' return on equity of -39.55% beat Aligos Therapeutics' return on equity.
Aligos Therapeutics has higher revenue and earnings than LENZ Therapeutics.
Summary
LENZ Therapeutics beats Aligos Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Aligos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aligos Therapeutics Competitors List
Related Companies and Tools
